Recursion Pharmaceuticals RXRX
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$11.11M (9 inflow days, 11 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 30.0% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 33.24% to 23.80% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| GWL Investment Management Ltd. | Mutual Fund | 2026/Q3 | +4,779,708 | 1.3% |
| FMR | Mutual Fund | 2026/Q3 | +11,390,097 | 1.8% |
| GWL Investment Management Ltd. | Mutual Fund | 2026/Q3 | +4,832,512 | 1.4% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +4,680,546 | 5.7% |
| Morgan Stanley | Public Company | 2026/Q3 | +3,481,256 | 1.0% |
| Morgan Stanley Investment Management Inc. | Mutual Fund | 2026/Q3 | +3,481,256 | 1.0% |
| ARK Investment Management LLC | Mutual Fund | 2026/Q3 | +3,407,393 | 7.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +3,174,188 | 8.6% |
| MFS Investment Management | Mutual Fund | 2026/Q3 | +2,391,009 | 0.4% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +1,525,733 | 0.2% |
| Creative Planning, Inc. | Mutual Fund | 2026/Q3 | +681,633 | 0.1% |
| First Trust Advisors L.P. | Mutual Fund | 2026/Q3 | +510,056 | 0.6% |
| TD Asset Management | Mutual Fund | 2026/Q3 | +432,400 | 0.1% |
| Voya Investment Management LLC | Mutual Fund | 2026/Q3 | +253,455 | 0.1% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +454,596 | 0.1% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 2 Nov 2026 | Blake Borgeson | Independent Director | Open Market Disposition | -40,000 | $3.88 | 5,979,863 |
| 1 Nov 2026 | Fred Hassan | Chair of the Board | Other Acquisition | +156,658 | – | 156,658 |
| 5 Oct 2026 | Robert Hershberg | Independent Director | Derivative Exercise and Sale | -25,000 | $5.00 | 73,732 |
| 5 Oct 2026 | Blake Borgeson | Independent Director | Automatic Disposition | -50,000 | $4.84 | 6,019,863 |
| 30 Sep 2026 | Dean Li | Director | Other Acquisition | +3,378 | – | 3,231,331 |
| 30 Sep 2026 | Zavain Dar | Independent Director | Other Acquisition | +4,607 | – | 156,947 |
| 14 Sep 2026 | Ben Taylor | CFO & President of Recursion UK | Sale to Issuer | -5,396 | $3.41 | 325,957 |
| 7 Sep 2026 | Najat Khan | Chief Executive Officer | Automatic Disposition | -22,408 | $3.52 | 159,729 |
| 31 Aug 2026 | Blake Borgeson | Independent Director | Automatic Disposition | -30,000 | $3.34 | 6,069,863 |
| 20 Aug 2026 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -77,290 | $3.39 | – |
| 19 Aug 2026 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -75,000 | $3.40 | – |
| 18 Aug 2026 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -100,000 | $3.28 | – |
| 17 Aug 2026 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -26,806 | $3.00 | – |
| 16 Aug 2026 | Ben Taylor | CFO & President of Recursion UK | Sale to Issuer | -25,018 | $3.16 | 319,874 |
| 16 Aug 2026 | David Hallett | Chief Scientific Officer | Sale to Issuer | -26,657 | $3.16 | 430,508 |
| 16 Aug 2026 | Najat Khan | Chief Executive Officer | Sale to Issuer | -80,498 | $3.16 | 182,137 |
| 12 Aug 2026 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -100,000 | $3.31 | – |
| 11 Aug 2026 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -50,000 | $3.37 | – |
| 9 Aug 2026 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -100,000 | $3.27 | – |
| 6 Aug 2026 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -100,000 | $3.25 | – |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 142,265,985 | 23.8% | 6.1 |
| 15 Oct 2026 | 161,926,247 | 30.2% | 4.4 |
| 30 Sep 2026 | 157,938,412 | 29.5% | 6.1 |
| 15 Sep 2026 | 178,724,433 | 33.4% | 12.6 |
| 31 Aug 2026 | 179,145,796 | 33.5% | 10.6 |
| 14 Aug 2026 | 177,923,359 | 33.2% | 13.4 |
No comments yet — be the first to weigh in on RXRX.
Sign in to join the discussion.